This would have to be the most compelling insight thus far in regards to potential for FebriDX in the US market. As long as the US-specific waivers and rebates have the effect we hope they do, then US distribution agreements and then forthcoming 2024 sales will be very, very interesting. GLTAH.
Ann: Change in substantial holding, page-72
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
